跳至主要内容
临床试验/NCT07745673
NCT07745673招募中不适用

Comparative Efficacy of Temporal Interference Stimulation at Different Targets in Parkinson's Disease

Zhongnan Hospital1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2026年6月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
18
试验地点
1
主要终点
Changes in motor symptoms in PD patients

研究概览

简要总结

This prospective, randomized, participant- and outcome-assessor-blinded, parallel-group exploratory trial will compare the target-dependent clinical, neuroimaging, and electrophysiological effects of temporal interference stimulation (TIS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) in patients with Parkinson's disease (PD).

Eighteen participants with idiopathic PD will be randomly assigned in a 1:1 ratio to the STN-TIS or GPi-TIS group. Participants will receive one 20-minute TIS session daily for 7 consecutive days. Motor symptoms will be assessed using the MDS-UPDRS Part III immediately before and after each daily stimulation session. Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention.

The primary outcomes are: (1) change in MDS-UPDRS Part III score from Day 1 before stimulation to Day 7 after stimulation; and (2) changes in regional spontaneous brain activity and seed-based functional connectivity measured using resting-state fMRI. Secondary outcomes are: (1) daily immediate changes in MDS-UPDRS Part III scores and the proportion of participants achieving at least 30% improvement at Day 7; and (2) changes in resting-state 64-channel EEG relative bandpower.

Safety and tolerability will be evaluated by monitoring adverse events and local skin reactions throughout the intervention. This study aims to provide preliminary evidence regarding target-dependent functional response patterns associated with STN- and GPi-targeted TIS in PD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult males or females aged ≥40 years;
  • Diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria, with age of onset ≥40 years;
  • Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response;
  • Hoehn and Yahr (H&Y) stage 1.5-2.5;
  • Able to walk independently for at least 5 minutes without assistive devices;
  • No severe freezing of gait (FOG);
  • Disease duration ≥2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions;
  • Stable medication regimen for at least 4 weeks prior to the study;
  • Signed informed consent form; subject or legal guardian is able to understand and willing to participate in this study.

排除标准

  • Presence of other neurological disorders that may affect the study (e.g., ...);
  • Mild cognitive impairment or above (MoCA ≤23);
  • Orthopedic or other medical conditions that may affect gait or balance;
  • Contraindications to MRI, such as claustrophobia;
  • History of antipsychotic, antidepressant, or other medications that may affect dopamine levels;
  • History of other severe psychiatric disorders;
  • History of epilepsy, traumatic brain injury, or implanted metallic devices in the brain or heart (e.g., stimulators, pacemakers) or other contraindications;
  • History of electroconvulsive therapy (ECT);
  • Currently participating in other gait- or balance-related intervention training;
  • Physician-diagnosed cardiovascular risk factors for exercise.

结局指标

主要结局

Changes in motor symptoms in PD patients

时间窗: Immediately before the first stimulation session on Day 1 and immediately after the final stimulation session on Day 7.

Motor symptoms will be assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III). All assessments will be conducted after withdrawal of antiparkinsonian medications for at least 12 hours. The change score will be calculated as the MDS-UPDRS Part III score immediately after the final stimulation session on Day 7 minus the score immediately before the first stimulation session on Day 1. A negative change value indicates improvement in motor symptoms.

Changes From Baseline in Regional Spontaneous Brain Activity and Seed-Based Functional Connectivity After 7 Days of TIS

时间窗: Baseline before the first stimulation session and immediately after completion of the 7-day intervention.

Regional spontaneous brain activity and functional connectivity will be assessed using resting-state functional magnetic resonance imaging. Regional spontaneous brain activity will be evaluated primarily using the standardized amplitude of low-frequency fluctuation (zALFF). Seed-based functional connectivity will be calculated using predefined subthalamic nucleus and globus pallidus internus seed regions, and correlation coefficients will be transformed to Fisher z values. For each imaging measure, the change value will be calculated as the post-intervention value minus the baseline value. Within-group changes and between-group differences will be evaluated to characterize stimulation-related and target-dependent brain functional response patterns.

次要结局

  • Immediate Changes in MDS-UPDRS Part III Scores and Clinical Response Rate During the 7-Day TIS Intervention(Immediately before and immediately after each stimulation session on Days 1 through 7; response rate assessed from immediately before the first stimulation session on Day 1 to immediately after the final stimulation session on Day 7.)
  • Change From Baseline in Resting-State 64-Channel EEG Relative Bandpower After 7 Days of TIS(Baseline before the first stimulation session and immediately after completion of the 7-day intervention.)

研究者

发起方
Zhongnan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

BinMei

chief Physician

Zhongnan Hospital

研究点 (1)

Loading locations...

相似试验